We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9147:TSENippon Express Holdings, Inc. Analysis

Data as of 2026-05-27 - not real-time

¥5,184.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Nippon Express is trading well above its 20‑day (¥4,533), 50‑day (¥4,044) and 200‑day (¥3,559) moving averages, confirming a strong bullish momentum on the chart. RSI of 88 signals an extreme overbought condition, and the MACD remains bullish with a widening histogram, suggesting the rally could persist in the very short term. However, the price sits just below the 52‑week high and the identified resistance at ¥5,243, leaving little upside before a potential pull‑back toward the support zone around ¥3,759. Volatility of 33% over the past 30 days combined with a low beta of 0.27 points to a stock that is highly volatile but relatively insulated from broader market moves. On the fundamentals side, the trailing PE of ~490 dwarfs the industry average of ~30, while the forward PE of 8.4 still implies a steep discount to the current price. The DCF‑derived fair value of ¥1,531 is far below the market price, yielding a -23% upside/downside metric, and the company’s profit margin of just 0.24% and ROE under 1% highlight weak earnings power. Despite a modest dividend yield of 1.98% and a low payout ratio (~9%), the balance sheet is strained with a debt‑to‑equity ratio above 100%, raising concerns about long‑term financial resilience.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in extreme overbought territory
  • Price near resistance at ¥5,243
  • Bullish MACD but limited upside

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant overvaluation vs DCF fair value
  • Low profitability and high debt levels
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Trailing PE far above industry norms
  • Weak earnings margins and ROE
  • Elevated debt‑to‑equity ratio

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin0.24%
P/E Ratio490.0
ROE0.92%
ROA-0.28%
Debt/Equity102.39
P/B Ratio1.5
Op. Cash Flow¥198.4B
Free Cash Flow¥72.9B
Industry P/E30.1

Technical Analysis

TrendBullish
RSI88.3
Support¥3,759.00
Resistance¥5,243.00
MA 20¥4,532.85
MA 50¥4,043.94
MA 200¥3,559.41
MACDBullish
VolumeStable
Fear & Greed Index91.36

Valuation

Fair Value¥1,531.34
Target Price¥3,995.00
Upside/Downside-22.94%
GradeOvervalued
TypeValue
Dividend Yield1.98%

Risk Assessment

Beta0.27
Volatility33.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.